|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
|
AU519567B2
(en)
|
1977-07-13 |
1981-12-10 |
Akzo Nv |
Psychopharmacological penta and hexa-peptides
|
|
USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
|
US4419446A
(en)
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
|
US4943533A
(en)
|
1984-03-01 |
1990-07-24 |
The Regents Of The University Of California |
Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
|
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
|
US4601903A
(en)
|
1985-05-01 |
1986-07-22 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
|
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
|
US5811128A
(en)
|
1986-10-24 |
1998-09-22 |
Southern Research Institute |
Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
US4849222A
(en)
|
1987-03-24 |
1989-07-18 |
The Procter & Gamble Company |
Mixtures for treating hypercholesterolemia
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
US4975278A
(en)
|
1988-02-26 |
1990-12-04 |
Bristol-Myers Company |
Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
JP2670680B2
(ja)
|
1988-02-24 |
1997-10-29 |
株式会社ビーエムジー |
生理活性物質含有ポリ乳酸系微小球およびその製造法
|
|
AU632065B2
(en)
|
1988-09-23 |
1992-12-17 |
Novartis Vaccines And Diagnostics, Inc. |
Cell culture medium for enhanced cell growth, culture longevity and product expression
|
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
ES2096590T3
(es)
|
1989-06-29 |
1997-03-16 |
Medarex Inc |
Reactivos biespecificos para la terapia del sida.
|
|
EP0491007B1
(en)
|
1989-09-08 |
1996-03-13 |
The Johns Hopkins University |
Structural alterations of the egf receptor gene in human gliomas
|
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5061620A
(en)
|
1990-03-30 |
1991-10-29 |
Systemix, Inc. |
Human hematopoietic stem cell
|
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
|
US5112596A
(en)
|
1990-04-23 |
1992-05-12 |
Alkermes, Inc. |
Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
DE69132709T2
(de)
|
1990-06-29 |
2002-06-20 |
Large Scale Biology Corp., Vacaville |
Melaninproduktion durch transformierte mikroorganismen
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
|
US5264365A
(en)
|
1990-11-09 |
1993-11-23 |
Board Of Regents, The University Of Texas System |
Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
|
|
US5508192A
(en)
|
1990-11-09 |
1996-04-16 |
Board Of Regents, The University Of Texas System |
Bacterial host strains for producing proteolytically sensitive polypeptides
|
|
CA2405246A1
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with alterred binding properties
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
DE69222303T2
(de)
|
1991-04-30 |
1998-01-22 |
Eukarion Inc |
Kationisierte antikörper gegen intrazelluläre eiweisse
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
|
AU665025B2
(en)
|
1991-09-23 |
1995-12-14 |
Cambridge Antibody Technology Limited |
Production of chimeric antibodies - a combinatorial approach
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
US5288502A
(en)
|
1991-10-16 |
1994-02-22 |
The University Of Texas System |
Preparation and uses of multi-phase microspheres
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
US5667988A
(en)
|
1992-01-27 |
1997-09-16 |
The Scripps Research Institute |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
|
|
AU675929B2
(en)
|
1992-02-06 |
1997-02-27 |
Curis, Inc. |
Biosynthetic binding protein for cancer marker
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
DE69334095T2
(de)
|
1992-07-17 |
2007-04-12 |
Dana-Farber Cancer Institute, Boston |
Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
|
|
ATE191853T1
(de)
|
1992-07-27 |
2000-05-15 |
Us Health |
Zielgerichte liposome zur blut-hirne schranke
|
|
EP0656064B1
(en)
|
1992-08-17 |
1997-03-05 |
Genentech, Inc. |
Bispecific immunoadhesins
|
|
MD1367C2
(ro)
|
1992-11-13 |
2000-11-30 |
Idec Pharmaceuticals Corporation |
Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
|
|
WO1995011010A1
(en)
|
1993-10-22 |
1995-04-27 |
Genentech, Inc. |
Methods and compositions for microencapsulation of antigens for use as vaccines
|
|
US6544952B1
(en)
|
1994-03-15 |
2003-04-08 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of glycoconjugates of the globo-H epitope and uses thereof
|
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
MX9707453A
(es)
|
1995-03-30 |
1997-12-31 |
Pfizer |
Derivados de quinazolina.
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
|
AU6267896A
(en)
|
1995-06-07 |
1996-12-30 |
Imclone Systems Incorporated |
Antibody and antibody fragments for inhibiting the growth oftumors
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
WO1997038123A1
(en)
|
1996-04-05 |
1997-10-16 |
Board Of Regents, The University Of Texas System |
Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
|
|
HU228446B1
(en)
|
1996-04-12 |
2013-03-28 |
Warner Lambert Co |
Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
|
|
US6231859B1
(en)
|
1996-12-02 |
2001-05-15 |
Aquila Biopharmaceuticals, Inc. |
Saponin adjuvant compositions
|
|
EP1500329B1
(en)
|
1996-12-03 |
2012-03-21 |
Amgen Fremont Inc. |
Human antibodies that specifically bind human TNF alpha
|
|
AUPO517897A0
(en)
|
1997-02-19 |
1997-04-11 |
Csl Limited |
Chelating immunostimulating complexes
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
US6083715A
(en)
|
1997-06-09 |
2000-07-04 |
Board Of Regents, The University Of Texas System |
Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
|
|
ZA986729B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
US7018637B2
(en)
|
1998-02-23 |
2006-03-28 |
Aventis Pasteur, Inc |
Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
|
|
AUPP807399A0
(en)
|
1999-01-08 |
1999-02-04 |
Csl Limited |
Improved immunogenic lhrh composition and methods relating thereto
|
|
AU776632B2
(en)
|
1999-02-17 |
2004-09-16 |
Glycominds Ltd. |
Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
|
|
WO2000048630A1
(en)
|
1999-02-17 |
2000-08-24 |
Csl Limited |
Immunogenic complexes and methods relating thereto
|
|
US7824687B2
(en)
|
1999-08-20 |
2010-11-02 |
Sloan-Kettering Institute For Cancer Research |
Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
|
|
US7854934B2
(en)
|
1999-08-20 |
2010-12-21 |
Sloan-Kettering Institute For Cancer Research |
Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
|
|
US6514221B2
(en)
|
2000-07-27 |
2003-02-04 |
Brigham And Women's Hospital, Inc. |
Blood-brain barrier opening
|
|
US20020065259A1
(en)
|
2000-08-30 |
2002-05-30 |
Schatzberg Alan F. |
Glucocorticoid blocking agents for increasing blood-brain barrier permeability
|
|
US7034036B2
(en)
|
2000-10-30 |
2006-04-25 |
Pain Therapeutics, Inc. |
Inhibitors of ABC drug transporters at the blood-brain barrier
|
|
US20030083299A1
(en)
|
2000-11-04 |
2003-05-01 |
Ferguson Ian A. |
Non-invasive delivery of polypeptides through the blood-brain barrier
|
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US20030104402A1
(en)
|
2001-01-23 |
2003-06-05 |
University Of Rochester |
Methods of producing or identifying intrabodies in eukaryotic cells
|
|
DE10121982B4
(de)
|
2001-05-05 |
2008-01-24 |
Lts Lohmann Therapie-Systeme Ag |
Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
|
|
JP4202250B2
(ja)
|
2001-07-25 |
2008-12-24 |
バイオマリン ファーマシューティカル インコーポレイテッド |
血液脳関門輸送を調節するための組成物および方法
|
|
CN1543350A
(zh)
|
2001-08-14 |
2004-11-03 |
|
糖半抗原和聚集的蛋白载体的免疫原性结合物
|
|
CA2467242A1
(en)
|
2001-11-20 |
2003-05-30 |
Seattle Genetics, Inc. |
Treatment of immunological disorders using anti-cd30 antibodies
|
|
US20030162695A1
(en)
|
2002-02-27 |
2003-08-28 |
Schatzberg Alan F. |
Glucocorticoid blocking agents for increasing blood-brain barrier permeability
|
|
AU2003219277A1
(en)
|
2002-03-14 |
2003-09-29 |
Medical Research Council |
Intracellular antibodies
|
|
AU2003294210A1
(en)
|
2002-07-31 |
2004-05-04 |
Seattle Genetics, Inc |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
|
WO2004042017A2
(en)
|
2002-10-31 |
2004-05-21 |
Genentech, Inc. |
Methods and compositions for increasing antibody production
|
|
CN101284136A
(zh)
|
2002-12-03 |
2008-10-15 |
布朗歇特洛克菲勒神经科学研究所 |
传输物质穿过血脑屏障的人工低密度脂蛋白载体
|
|
CA2513113A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
|
US20060035267A1
(en)
|
2003-04-09 |
2006-02-16 |
Livingston Philip O |
Optimal polyvalent vaccine for cancer
|
|
GB0316294D0
(en)
|
2003-07-11 |
2003-08-13 |
Polytherics Ltd |
Conjugated biological molecules and their preparation
|
|
AU2004268001B2
(en)
|
2003-08-25 |
2010-04-22 |
Univax, Llc |
Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (BORIS)
|
|
US20050089473A1
(en)
|
2003-09-10 |
2005-04-28 |
Cedars-Sinai Medical Center |
Potassium channel mediated delivery of agents through the blood-brain barrier
|
|
EP1723422A2
(en)
|
2004-03-05 |
2006-11-22 |
The Scripps Research Institute |
High throughput glycan microarrays
|
|
KR100958505B1
(ko)
|
2004-07-18 |
2010-05-17 |
씨에스엘 리미티드 |
면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
|
|
CA2574090A1
(en)
|
2004-07-18 |
2006-12-21 |
Coley Pharmaceutical Group, Ltd. |
Methods and compositions for inducing innate immune responses
|
|
CN103361301A
(zh)
|
2005-03-31 |
2013-10-23 |
斯丹姆涅恩有限公司 |
高度纯化来自羊膜的细胞群
|
|
HRP20110498T1
(hr)
|
2005-10-07 |
2011-08-31 |
Exelixis |
Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
|
|
ES2542141T3
(es)
|
2005-10-17 |
2015-07-31 |
Sloan Kettering Institute For Cancer Research |
Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
|
|
US8444971B2
(en)
|
2006-11-27 |
2013-05-21 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
|
WO2009035494A2
(en)
|
2007-07-30 |
2009-03-19 |
The Scripps Research Institute |
Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease
|
|
CA2701612A1
(en)
|
2007-10-05 |
2009-04-09 |
Takeda Pharmaceutical Company Limited |
Neuromedin u derivative
|
|
WO2009121564A1
(en)
|
2008-03-31 |
2009-10-08 |
Freie Universität Berlin |
Drug conjugates with polyglycerols
|
|
JP5706815B2
(ja)
|
2008-04-08 |
2015-04-22 |
スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ |
トリテルペンであるサポニン、その合成法および使用
|
|
TWI461531B
(zh)
*
|
2008-05-07 |
2014-11-21 |
Shi Lung Lin |
使用可誘導之重組核醣核酸生成不具癌細胞特性之類胚胎幹細胞
|
|
ES2477549T3
(es)
*
|
2008-06-16 |
2014-07-17 |
Academia Sinica |
Diagnóstico del cáncer según la concentración de anticuerpos contra Globo H y sus fragmentos
|
|
CN102065868A
(zh)
*
|
2008-06-16 |
2011-05-18 |
中央研究院 |
诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途
|
|
CN105535955B
(zh)
*
|
2009-06-16 |
2019-04-23 |
中央研究院 |
Globo h及含新颖糖脂质佐剂的相关抗癌疫苗
|
|
EP2347769A1
(en)
|
2010-01-20 |
2011-07-27 |
Glycotope GmbH |
Cancer stem cell markers and uses thereof
|
|
US9493580B2
(en)
|
2010-06-11 |
2016-11-15 |
Sloan-Kettering Institute For Cancer Research |
Multivalent glycopeptide constructs and uses thereof
|
|
US9175326B2
(en)
|
2011-03-03 |
2015-11-03 |
University Of Maryland, Baltimore |
Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from streptococcus pneumoniae
|
|
EP2500035A1
(en)
|
2011-03-15 |
2012-09-19 |
Icon Genetics GmbH |
Pharmaceutical formulation containing immunglobulin
|
|
WO2012171020A1
(en)
|
2011-06-10 |
2012-12-13 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
CA2862925C
(en)
|
2012-02-10 |
2020-01-21 |
University Of Maryland, Baltimore |
Chemoenzymatic glycoengineering of antibodies and fc fragments thereof
|
|
PE20190658A1
(es)
|
2012-02-24 |
2019-05-08 |
Abbvie Stemcentrx Llc |
Moduladores y metodos de empleo novedosos
|
|
NZ631034A
(en)
|
2012-03-16 |
2016-06-24 |
Merck Patent Gmbh |
Targeting aminoacid lipids
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
EP3792272A1
(en)
|
2013-01-04 |
2021-03-17 |
OBI Pharma, Inc. |
Vaccines with higher carbohydrate antigen density and novel saponin adjuvant
|
|
US10307471B2
(en)
|
2013-05-02 |
2019-06-04 |
National Institute Of Advanced Industrial Science And Technology |
Immunity inducer for saccharide antigens
|
|
AU2014391422A1
(en)
|
2013-09-17 |
2015-12-17 |
Obi Pharma, Inc. |
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
|
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10150818B2
(en)
*
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
EP3119424A4
(en)
|
2014-03-19 |
2017-09-13 |
MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital |
Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
|
|
EP2927328B1
(en)
|
2014-04-01 |
2018-10-10 |
Miltenyi Biotec GmbH |
SSEA4 and ST3GAL2 as chemotherapeutic drug response biomarkers
|
|
CA2941029C
(en)
|
2014-04-10 |
2021-02-16 |
Obi Pharma Inc. |
Antibodies, pharmaceutical compositions and uses thereof
|
|
US10092645B2
(en)
|
2014-06-17 |
2018-10-09 |
Medimmune Limited |
Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
|
|
CN106661129B
(zh)
*
|
2014-08-19 |
2021-02-05 |
美天施生物科技有限两合公司 |
对ssea4抗原具有特异性的嵌合抗原受体
|
|
US20160339089A1
(en)
|
2014-09-15 |
2016-11-24 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycoconjugate compositions and uses thereof
|
|
JP2018510844A
(ja)
|
2015-01-24 |
2018-04-19 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
がんマーカーおよびその使用方法
|
|
CA2973886A1
(en)
|
2015-01-30 |
2016-08-04 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
CA2991040A1
(en)
|
2015-06-29 |
2017-01-05 |
The Johns Hopkins University |
Immune checkpoint chimeric receptors therapy
|
|
EP3323886B1
(en)
|
2015-07-16 |
2020-10-21 |
Daiichi Sankyo Company, Limited |
Endos mutant enzyme
|
|
KR20180050339A
(ko)
|
2015-09-04 |
2018-05-14 |
오비아이 파머 인코퍼레이티드 |
글리칸 어레이 및 사용 방법
|
|
KR20180077181A
(ko)
|
2015-10-07 |
2018-07-06 |
오비아이 파머 인코퍼레이티드 |
신규한 탄수화물 항체, 약제학적 조성물 및 이들의 용도
|
|
AU2017239637A1
(en)
|
2016-03-29 |
2018-11-15 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
|
CN109379889A
(zh)
|
2016-04-22 |
2019-02-22 |
台湾浩鼎生技股份有限公司 |
通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
|
|
GB201611535D0
(en)
|
2016-07-01 |
2016-08-17 |
King S College London |
Methods and compositions for treating cancer with siglec-9 activity modulators
|
|
KR20230117482A
(ko)
|
2016-07-27 |
2023-08-08 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
|
WO2018023121A1
(en)
|
2016-07-29 |
2018-02-01 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
|
EP3500594A4
(en)
|
2016-08-22 |
2020-03-11 |
Cho Pharma Inc. |
ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
|
|
TWI822055B
(zh)
|
2016-11-21 |
2023-11-11 |
台灣浩鼎生技股份有限公司 |
共軛生物分子、醫藥組成物及方法
|